GlassScriptPhysician profile
Jeffrey M Steinberg
NPI 1497706212
$76,058.93
in general payments reported to CMS, 2019-2025
43 companies · $7,431 in 2025
The $7,431 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,928 · 2020: $5,287 · 2021: $26K · 2022: $16K · 2023: $8,116 · 2024: $7,078 · 2025: $7,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,900.00 |
| Food and Beverage | $3,724.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,672.73 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $12,654.02 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Allergan, INC. | $2,276.76 | 2019-2021 | |
| Lilly USA, LLC | $794.79 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Janssen Pharmaceuticals, INC | $513.57 | 2021-2023 | Ponvory |
| Jazz Pharmaceuticals INC. | $492.34 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $470.67 | 2020-2023 | |
| Eisai INC. | $325.33 | 2020-2025 | |
| Pfizer INC. | $266.04 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $235.80 | 2019-2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $225.65 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $208.30 | 2021 | |
| Tanabe Pharma America, INC. | $203.32 | 2019-2025 | Radicava |
| Mallinckrodt Hospital Products INC. | $156.55 | 2020-2024 | Acthar |
| Genzyme Corporation | $121.04 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.